<?xml version="1.0" encoding="UTF-8"?>
<p id="p0080">It has indeed become a delicate balancing act to advance cancer science while keeping cancer patients, many of whom are immunosuppressed, and staff safe and protected. Many researchers and institutions have had to pause their laboratory work during this period. Although clinical trials accrual has sharply declined, NCI is working to ensure that cancer center trials offering potentially life-saving therapies and trials where there are no other viable treatment options beyond a clinical trial for patients remain available.</p>
